Pharma BD Deal Intelligence
The $6.9B deal that rewrote the antibody-drug conjugate playbook. AstraZeneca paid $1.35B upfront for Enhertu, which showed unprecedented activity across five tumor types including HER2-low breast cancer—a category that didn't exist before the DESTINY trials.
AstraZeneca and Daiichi Sankyo entered a global collaboration to jointly develop and commercialize trastuzumab deruxtecan (Enhertu) in a deal worth up to…
AstraZeneca turns again to Daiichi Sankyo for a major cancer drug deal. AstraZeneca paid $1.35 billion upfront to license Enhertu in 2019 in a deal that could…
AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019, with AstraZeneca paying…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
AstraZeneca entered a global licensing and co-development collaboration with Daiichi Sankyo for Enhertu (trastuzumab deruxtecan), a HER2-directed antibody-drug conjugate. AstraZeneca paid $1.35 billion upfront with up to $5.55 billion in regulatory and sales milestones, for a total potential deal value of $6.9 billion. Daiichi Sankyo retained exclusive rights in Japan and manufacturing responsibility.
Assessment window: 5yr post-close.
120K US cases/yr
HER2-low breast cancer (IHC 1+ or 2+/ISH-) represents ~40-50% of all breast cancers, a massive population previously considered HER2-negative. DESTINY-Breast04 showed Enhertu benefit in this population, effectively creating a new treatable subtype and dramatically expanding the addressable market.
The HER2-low designation is a paradigm shift, expanding Enhertu's addressable population 3-4x beyond traditional HER2+. This drove AZ/Daiichi to expand their deal with additional ADC collaborations (dato-DXd, HER3-DXd). HER2-ultralow (IHC 0 with faint staining) is now being explored in DESTINY-Breast06.
55K US cases/yr · $8.6B Global HER2+ BC Treatment (2024) · $4.6B Enhertu Global Revenue (2024)
HER2-positive breast cancer accounts for approximately 15-20% of invasive breast cancer and is defined by HER2 (ERBB2) gene amplification or protein overexpression, historically associated with aggressive clinical behavior and worse prognosis. HER2 status is determined by IHC and/or in situ hybridization per ASCO/CAP guidelines. The treatment paradigm has been transformed by HER2-directed therapies: trastuzumab, pertuzumab, T-DM1, tucatinib, and the ADC trastuzumab deruxtecan, which has expanded into HER2-low disease.
Enhertu competes with Herceptin (Roche, biosimilar era), Kadcyla (Roche), and Tukysa (Seagen/Pfizer). Enhertu's bystander effect and expanding indications (gastric, NSCLC, HER2-low) drive growth. First-line approval with pertuzumab positions it to challenge the established Herceptin+Perjeta backbone.
AstraZeneca paid $1.35B upfront with up to $5.55B in milestones to co-develop Enhertu (trastuzumab deruxtecan) HER2 ADC.
Enhertu approved in multiple HER2+ indications including breast, gastric, and NSCLC.
Combined Enhertu sales hit $3.7B in 2024, up 46% YoY. Becoming one of top oncology drugs globally.
FDA approved Enhertu for first-line HER2+ breast cancer, triggering $150M milestone payment.
Combined global sales of Enhertu recorded by Daiichi Sankyo and AstraZeneca reached $4,982m in FY2025, up from $3,754m in FY2024 (+33%). US in-market sales were $2,446m. Source: AstraZeneca FY2025 results (SEC Form 6-K).
FDA approved Enhertu for two HER2-positive early breast cancer indications: neoadjuvant Enhertu followed by taxane/trastuzumab/pertuzumab (DESTINY-Breast11; pCR 67.3% vs 56.3%) and adjuvant Enhertu in patients with residual invasive disease (DESTINY-Breast05; 53% reduction in risk of invasive disease recurrence or death vs T-DM1). First move of the ADC into the curative-intent early-stage setting.
Blockbuster ADC Partnership. Assessment of AstraZeneca PLC's $6.9B acquisition of Daiichi Sankyo Co. Ltd. and its strategic outcomes.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Daiichi Sankyo Company, Limited (this deal) | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2019 deals · AstraZeneca PLC deals · Oncology deals